City of Hope's Ravi Salgia Discovers New Biomarker Link in Nonsmall Cell Lung Cancer
December 7, 2017 | Elise Lamar
Ravi Salgia, M.D., Ph.D., recently published in Scientific Reports about a novel and promising link between two NSCLC biomarkers. The study might help oncologists match patients with effective drug interventions against specific forms of NSCLC.
Advanced Lung Cancer Patient: ‘I’m Not About to Go Quietly into the Night’
November 30, 2017 | Julia F.
Julie F., 59, of Wisconsin, survived advanced small cell lung cancer after 29 rounds of chemotherapy, five weeks of radiation and experimental immunotherapy. This is her story.
City of Hope’s Ravi Salgia, M.D., Ph.D., honored for outstanding contributions to oncology
June 2, 2017 | Letisia Marquez
City of Hope’s Ravi Salgia, M.D., Ph.D., whose accomplishments as a medical oncologist and researcher have helped shape modern cancer medicine, was celebrated at ASCO by the Indo-American Cancer Association (IACA) for his contributions to the field.
Blood and urine tests could identify lung cancer mutation without biopsy
January 26, 2015 | Nicole White
As treatments for lung cancer become more targeted and effective, the need for better technology to detect lung cancer mutations becomes increasingly important. A new clinical study at City of Hope is examining the feasibility of using blood and urine tests to detect lung cancer mutations, potentially allowing for targeted cancer treatments without an invasive biopsy.
For November, 30 facts (one a day) about lung cancer
November 1, 2014 | Nicole White
Lung cancer is a men’s health issue. It’s a women’s health issue. The truth is, anyone can get lung cancer. November is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer death. Today 400,000 survivors live in the U.
ASCO 2014: New drug may overcome lung cancer's chemotherapy resistance
May 21, 2014 | Hiu Chung So
For lung cancer patients whose tumors are resistant to a class of chemotherapy called tyrosine kinase inhibitors (TKI), a drug called cabozantinib may be able to undo that resistance, according to a new City of Hope study.
New options needed, and likely, for ALK-positive lung cancer
March 30, 2014 | Tami Dennis
People with what’s known as ALK-positive lung cancer usually develop resistance to crizotinib, the primary drug used to treat their disease. The drug’s limitations are all the more significant because its approval in 2011 was considered a crucial advance against this type of nonsmall cell lung cancer.
Lung cancer: 7 breakthroughs in research, treatment, diagnosis
October 30, 2013 | C. Kitchens
Lung cancer is not unbeatable. Each day, doctors and researchers in City of Hope’s Lung Cancer and Thoracic Oncology Program aggressively pursue innovative approaches to bring new treatments and cures to patients with all forms of this devastating disease.
Meet our doctors: Karen Reckamp on lung cancer's mystery risks
October 26, 2013 | Kim Proescholdt
Lung cancer is the leading cause of cancer death in men and women in the United States, causing more deaths than colon, breast and prostate cancer combined. Health professionals agree that tobacco use is the No.
Drug fights lung cancer by taking away its 'chaperone' (VIDEO)
June 19, 2013 | Hiu Chung So
Chaperone proteins earned their name because they help other proteins assemble, fold, stabilize and degrade in proper manner. But in cancer, they can be hijacked to maintain and promote proteins essential for tumor growth as well.